Adage Capital is a new significant holder; monitor future 13G amendments for stake changes and any 8-K earnings or pipeline updates that could influence their position. The passive filing suggests no near-term activist engagement.
XLO drugs
XLO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $8.24entry
- T+1 · 4d ago −2.00%α −1.64% · $8.08
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Adage Capital Management disclosed a 7.06% passive stake in Xilio Therapeutics via a new Schedule 13G, holding 464,598 shares as of September 30, 2026. This is a new filer for Xilio, adding a notable hedge fund investor to the register, though the stake is passive with no control intent.
Key Financial Metrics
Key Facts
- Adage Capital Management disclosed 464,598 shares of Xilio Therapeutics common stock, representing 7.06% of shares outstanding.
- Stake is based on 6,580,153 shares outstanding as of August 10, 2026, per the company's Q2 2026 10-Q.
- Filing is a new Schedule 13G, not an amendment; Adage was not previously a reported 5% holder.
- Adage certifies passive intent under Rule 13d-1(b), with no purpose of changing or influencing control.
- Filing date is November 12, 2026, with beneficial ownership as of September 30, 2026.
Financial Impact
7.06% stake valued at approximately $3.95M based on $56M market cap
Risk Factors
- Passive 13G status could change to 13D if Adage later engages actively, but no indication in this filing.
- Micro-cap biotech with $56M market cap; large holder exits could pressure stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000919574-26-007551 |
| Document: 0000919574-26-007551-index-headers.html | 0000919574-26-007551 |
| Document: 0000919574-26-007551-index.html | 0000919574-26-007551 |
| Document: 0000919574-26-007551.txt | 0000919574-26-007551 |
Track record
16 reports on XLO
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +19.92% at T+60 after the May 12, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $7.70 Now $7.70 −0.00% settles Nov 24
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $7.96 Now $7.70 −3.27% settles Nov 23
- Nov 12, 20264d ago SC 13G Neutral 4/10 Viewing Entry $8.24 Now $7.70 −6.55% settles Nov 19
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $8.53 Now $7.70 −9.73% settles Nov 17
- Oct 26, 202621d ago Press Release Neutral 4/10 Entry $7.31 to $8.03 Now $7.70 +5.34% ▲ +9.85% +11.11% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 No price data
- Aug 12, 202613w ago Press Release Bullish 7/10 Entry $9.05 to $9.41 Now $7.70 −14.92% ▲ +3.98% +4.42% vs SPY
- Jun 1, 202624w ago EFFECT Bearish 5/10 Entry $8.25 to $7.70 Now $7.70 +6.67% ▲ +6.67% +3.92% vs SPY
- May 27, 202624w ago S-3/A Neutral 4/10 Entry $8.52 to $8.15 Now $7.70 −9.62% ▼ −4.40% −4.35% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers